Core Viewpoint - LifeMD Inc is strategically focusing on its core telehealth and pharmacy services by divesting its WorkSimpli business, which is expected to enhance operational efficiency and market share growth [1][5]. Financial Performance - The stock price target set by Loop Capital Markets is $10, indicating a potential upside of approximately 42.27% from its current trading price of $3.87, which reflects a slight decrease of 4.68% [2][5]. - LifeMD is trading at a low multiple of 0.796 times its trailing twelve-month sales, suggesting potential upside if multiples revert to higher levels [3]. Market Activity - The stock has fluctuated between a low of $3.86 and a high of $4.30 today, with a market capitalization of approximately $186.3 million and a trading volume of 1,062,494 shares on the NASDAQ exchange [4]. - Over the past year, the stock reached a high of $15.84 and a low of $2.56, indicating significant volatility [4]. Growth Drivers - The recent launch of the Wegovy pill is anticipated to drive growth within LifeMD's GLP-1 vertical, further strengthening its market position [3][5].

Core Viewpoint - Hims & Hers Health continues to demonstrate strong growth potential, with significant revenue increases and a robust outlook for future performance [1][11]. Revenue Performance - In Q3, Hims & Hers reported a 49% year-over-year increase in revenue, reaching $599 million, surpassing both its guidance and analyst expectations [2][7]. - Monthly online revenue per subscriber increased by 19% to $80, while the subscriber base grew by 21% to over 2.47 million [3][7]. Subscriber Growth and Transition - The number of customers utilizing personalized treatment plans surged by 50%, with those using at least one personalized subscription rising by 80% to 1.6 million, accounting for over 65% of the subscriber base [4][3]. - Excluding the impact of the transition to personalized treatments, subscriber growth exceeded 40% [3]. Financial Metrics - Adjusted EBITDA increased by 53% from $51.1 million to $78.4 million, while earnings per share (EPS) was reported at $0.06, missing the analyst consensus of $0.09 [6][7]. - Gross margin experienced a decline of 500 basis points year-over-year to 74%, with operating expenses slightly decreasing to 72% of revenue [5][7]. Future Guidance - Hims & Hers narrowed its 2025 revenue forecast to between $2.335 billion and $2.355 billion and adjusted EBITDA guidance to a range of $307 million to $317 million [7]. - For Q4, the company anticipates revenue between $605 million and $625 million, with adjusted EBITDA expected to be between $55 million and $65 million [8]. Strategic Developments - The company is in discussions with Novo Nordisk to potentially offer Wegovy injections and oral Wegovy on its platform, following a previous collaboration that ended earlier this year [9]. Valuation Metrics - The stock trades at a forward price-to-earnings (P/E) ratio of approximately 32.5 for 2026, with a price/earnings-to-growth (PEG) ratio around 1, indicating potential undervaluation [12][13]. - Based on price-to-sales multiples, the stock is valued at 3.6 times 2026 analyst estimates, suggesting attractive valuation given its growth outlook [13].